Under Trump's executive order, marijuana will be moved from Schedule I, which includes banned substances such as heroin, LSD, ...

An update from Quantum Biopharma ( ($TSE:QNTM) ) is now available. On December 23, 2025, Quantum BioPharma announced it has completed oral dosing ...

See why TG Therapeutics, Inc. earns a Buy rating, with insights on Briumvi's efficacy and market growth in multiple sclerosis ...

The new proposed federal classification of marijuana would allow more research, and would let cannabis businesses take normal ...

Explore how engineered extracellular vesicles can enhance antigen-specific regulatory T cells to improve immune response.

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

“We are very pleased that dosing is now complete in both 180-day chronic toxicity studies. These studies allow us to advance the Lucid-MS drug development program as they are critical components to ...

A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has ...

Dubai, UAE: The Emirates Drug Establishment (EDE) has announced the approval of Itvisma™ (onasemnogene abeparvovec), a gene therapy that uses an adeno-associated viral vector to treat spinal muscular ...